Compare
AbbVie vs Neurocrine Biosciences (ABBV vs NBIX)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year AbbVie (ABBV) returned +34.4% and Neurocrine Biosciences (NBIX) +7.1%; so far this year the figures are +27.5% and +16.1%.
AbbVie is the larger company by market value, about 30.9 times the size of Neurocrine Biosciences.
On trailing earnings, ABBV trades at 50.1 times and NBIX at 24.4 times.
Revenue grew +10.7% at ABBV and +38.0% at NBIX over the last year.
ABBV yields 2.38%. NBIX pays no dividend.
Data as of the latest close. Not investment advice.
Relative performance
| ABBV | NBIX | |
|---|---|---|
| Price | $291.31 | $164.63 |
| 1-day | +1.07% | +3.05% |
| YTD | +27.49% | +16.08% |
| 1 year | +34.39% | +7.08% |
| 3 years | +104.47% | +47.60% |
| Market cap | $514.9B | $16.7B |
| P/E | 50.1 | 24.4 |
| P/S | 7.80 | 4.50 |
| P/B | — | 4.30 |
| Revenue growth | +10.70% | +38.00% |
| EPS growth | +340.20% | +61.20% |
| Gross margin % | 73.7 | 97.8 |
| Net margin % | 15.7 | 19.0 |
| ROE % | — | 18.1 |
| Debt / equity | — | 0.00 |
| FCF yield % | 3.7 | 6.2 |
| Dividend yield % | 2.38 | — |
| Beta | -0.03 | 0.64 |
| RSI (14) | 59.7 | 69.4 |
| Technical rating |